02185 BIOHEART-B
- 2.140
- -0.060-2.73%
BIOHEART-B News
百心安-B：2023年報
OrbiMed Capital LLC sold 1,548,600 H shares of Baixinan-B (02185.HK) worth approximately HK$3.7941 million
On March 26, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 26, OrbiMed Capital LLC sold $1,548,600 H shares worth HK$3.7941 million at an average price of HK$2.45 per share on March 22. After the sale, OrbiMed Capital LLC's latest shareholding was 11.3564 million shares, and the good position ratio dropped from 5.46% to 4.81%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange,
Baixinan-B (02185.HK) lost about 189 million yuan in 2023
Gelonghui, March 25 | Baixinan-B (02185.HK) announced that for the year ended December 31, 2023, the Group's net loss was approximately RMB 188.8 million, a decrease of 18.2% from approximately RMB 230.9 million in 2022. R&D expenditure for the year ended 31 December 2023 was approximately RMB 111.7 million, a decrease of 29.2% from approximately RMB 157.8 million recorded in 2022. As of December 31, 2023, the net asset liability ratio was 5.4% (2022:6.8%).
BIOHEART-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Baixinan-B (02185.HK) plans to hold a board meeting on March 25 to approve the annual results
Gelonghui, March 13 | Baixinan-B (02185.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if any).
BIOHEART-B: DATE OF BOARD MEETING
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Financial News Agency Venture Capital Connect: In November, domestic healthcare financing of 5.931 billion yuan increased 49% month-on-month, and innovative drugs led the popularity
① In November 2023, there were 109 financing incidents in the domestic healthcare sector (excluding IPOs, targeted increases, etc.), a year-on-year decrease of 31% and an increase of 76% over the previous year; ② The total amount of financing disclosed in the healthcare sector during the same period was about 5.931 billion yuan, a decrease of 6% over the previous year and an increase of 49% over the previous year.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
How will the pharmaceutical sector go next year? Innovative drugs are moving from “quantitative change” to “qualitative change”, and the localization process of devices is accelerating
“Science and Technology Innovation Board Daily”, December 10 (Editor Qiu Siyu) As we approach the end of the year, a number of organizations have released annual strategy reports one after another, outlining market trends in 2024.
What pharmaceutical segmentation directions are worth paying attention to next year after making a major repurchase of the innovative drug sector by Yakuming Biotech to sweep away the haze?
① The trend of Pharmaceutical Biology (Shenwan) since the beginning of the year is still at the low point of September 2022, and the valuation is also at the low point of previous years; ② many institutions believe that the pharmaceutical industry is at the bottom; ③ innovative drugs and overseas travel have become key areas of focus for various institutions.
Changes in Hong Kong stocks | Baixinan-B (02185) rose nearly 7% Medtronic RDN products were approved in the US, and the company's RDN products are progressing ahead in China
Baixinan-B (02185) rose nearly 7%. As of press release, it was up 6.99% to HK$4.44, with a turnover of HK$1,218,000.
After more than ten years of experience, Medtronic RDN was approved to begin commercialization
Compared to other Red Sea markets, this RDN circuit, which is still in the Blue Ocean market, not only has global medical device giants betting, but also many excellent domestic local companies struggling to catch up.
Baixinan (2185.HK): Medtronic RDN products have been approved in the US and it is expected that the domestic commercialization process will soon begin
Event: On November 17, 2023, Medtronic announced that Symplicity, an interventional product for treating high blood pressure, has been approved by the FDA and will begin commercialization immediately. RDN products will soon be commercialized in the US. cutoff
Express News | Societe Generale Securities: Optimistic about future investment opportunities in innovative drugs and innovative devices
Express News | CITIC Securities: The healthcare industry collapsed in 2024, and the layout revolved around three main lines
Analysis
Price Target
No Data
